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Disorders of consciousness (DOC) are one of many neurological
diseases for which there is still no curative treatment. The majority
of therapeutic options performed in these patients have focused on
accelerating clinical recovery through pharmacological interven-
tions, environmental stimulation or, more recently, using neuromo-
dulatory brain stimulation techniques, among others [1]. Vagus
nerve stimulation (VNS), has recently been used in neurorehabilita-
tion based on its effects on cortical plasticity [2]. Two recent case
reports using VNS have shown promising results for increasing
the level of consciousness in two patients in Vegetative State/Unre-
sponsive Wakefulness Syndrome (VS/UWS) after severe traumatic
brain injury [3,4]. However the role of VNS in DOC has not been sys-
tematically studied.
We prospectively enrolled chronic adult patients with DOC who
weremore than six months post injury, and were receiving rehabil-
itation in our facility between May 2018 and January 2019. We
included only patients with no changes in at least five Coma Recov-
ery Scale-Revised (CRS-R) scores performed weekly in the four
weeks before inclusion. The experimental intervention consisted
of forty, 30-minute transauricular (left tragus) VNS (Parasym®
CE) sessions administered twice a day (five days per week). Stimu-
lation parameters (sinusoidal waveform; pulse width: 250 us; fre-
quency: 20 Hz; amplitude: 1.5 mA) were chosen according to
previous studies [4].
All patients included in the study were assessed with the CRS-R
at baseline (T0), week 1 (T1), week 2 (T2), week 3 (T3), and week 4
(T4: end of treatment) with a further follow-up 4 weeks after the
termination of stimulation. Each subject’s heart rate (HR) and blood
pressure (BP) were monitored during all treatment sessions. Addi-
tionally, during the first VNS session, subjects were monitored by a
multimodal monitor that included continuous ECG.
Our primary outcome measure was the number of subjects pre-
senting any improvement in at least one item in the CRS-R evalua-
tion at one time point. We also recorded the type and number ofs article under the CC BY-NC-ND lial responses. Safety was primarily assessed by analysis of
t-emergent adverse events (TEAEs). The main feasibility
endpoint was the number of participants who completed the ther-
apy protocol.
The final sample included 14 patients aged 40.2 (SD: 16.1) years
(12.1 ± 6.4 months postonset) with acquired brain injury. Six pa-
tients were in VS/UWS and eight patients were in Minimally
Conscious State (MCS) (Table 1).
Although the clinical diagnosis remained unchanged during the
study, we found a significant improvement in total CRS-R scores at
the end of the 1-month follow-up (p ¼ 0.04). None of the VS pa-
tients at admission showed any change in the CRS-R total scores,
while five of the eight MCS patients at admission showed an
improvement during the duration of the study (p ¼ 0.02). The
CRS-R improved in only one MCS patient at the end of the treat-
ment (T4). This patient and four more subjects showed improve-
ment at one month follow-up (T4þ4). Four responders showed
an improvement in only one CRS-R subscale (motor subscale:
n ¼ 3; visual subscale: n ¼ 1), while one responder showed im-
provements in more than one CRS-R subscale.
Eight mild AEs were reported from a total of 560 sessions per-
formed. All AEs were considered common medical conditions
without obvious relations to VNS. No relevant ECG alterations
were observed. HR and BP were not modified by VNS (p > 0.05 in
all comparisons). Two patients missed one of the VNS sessions pro-
grammed for nonclinical reasons. The missed session was replaced
in these two cases at the end of the stimulation period.
To our knowledge this is the first reported case series addressing
feasibility, safety and efficacy issues in a sample of patients with
DOC, including VS/UWS and MCS patients of different etiologies
and chronicity. Our results suggested that the use of transauricular
VNS is feasible and preliminarily safe in DOC patients and that it
may improve behavioral responses when applied to MCS patients.
Neurophysiological and neuroimaging data have suggested that
clinically defined MCS patients show partially preserved brain con-
nectivity and maintain limited but effective cortical plastic proper-
ties, which may allow them to present better behavioral responses
and better clinical responses to therapeutic interventions than VS/
UWS subjects [5]. This aspect could explain the differences in im-
provements experienced by our MCS patients when compared to
those in VS/UWS.
Four of our five responders showed appreciable clinical
improvement in the motor subscale of the CRS-R. Different studies
have shown that VNS is able to effectively modulate motor re-
sponses and facilitate motor learning through GABAergic neuromo-
dulation mechanisms [6]. The GABAergic neurotransmission
system has also been implicated in the clinical improvementcense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Results.
ID Age (Years) Gender Etiology Disease Duration (Months) CRS-R (Diagnosis)
T0: Baseline
CRS-R (Diagnosis)
T4: End of treatment
CRS-R (Diagnosis)
T4þ4weeks: Follow-up
001 65 Female Hemorrhage 27 6 (VS/UWS) 6 (VS/UWS) 6 (VS/UWS)
002 45 Male Hemorrhage 7 6 (VS/UWS) 6 (VS/UWS) 6 (VS/UWS)
003 20 Male Traumatic 10 8 (VS/UWS) 8(VS/UWS) 8 (VS/UWS)
004 70 Female Anoxia 12 8 (VS/UWS) 8(VS/UWS) 8 (VS/UWS)
005 28 Male Anoxia 21 8 (VS/UWS) 8(VS/UWS) 8 (VS/UWS)
006 39 Male Anoxia 6 8 (VS/UWS) 8(VS/UWS) 8 (VS/UWS)
007 ® 30 Female Hemorrhage 8 8 (MCS-) 8 (MCS-) 9 (MCS-)
008 ® 35 Male Traumatic 9 9 (MCS-) 9 (MCS-) 10 (MCS-)
009 38 Male Traumatic 10 10 (MCS-) 10 (MCS-) 10 (MCS-)
010 ® 21 Male Traumatic 15 10 (MCS-) 10 (MCS-) 12 (MCS-)
011 ® 21 Female Traumatic 12 11 (MCS-) 11 (MCS-) 12 (MCS-)
012 45 Male Traumatic 7 12 (MCS-) 12 (MCS-) 12 (MCS-)
013 46 Female Traumatic 20 14 (MCS-) 14 (MCS-) 14 (MCS-)
014 ® 60 Female Anoxia 6 14 (MCSþ) 15 (MCSþ) 17 (MCSþ)
CRS-R, Coma Recovery Scale-Revised; MCS, Minimally Conscious State; VS/UWS, Vegetative State/Unresponsive Wakefulness Syndrome. Responders are marked with an R.
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and intrathecal baclofen [1].
The benefits of VNS require time to emerge. Basic principles of
experience-dependent neural plasticity suggest that intensive
repetition over time is necessary for a therapeutic procedure to
induce and sustain clinically significant changes [7].Similarly, clin-
ical improvements after repetitive tDCS have been described in
DOC patients even years after the brain injury [8], suggesting that
although some neurophysiological changes can be detected after
few sessions, persistent clinical changes may require a continuous
application of the technique to be detected.
The evaluation of cardiovascular parameters and the low fre-
quency of AE detected in our study confirms that tVNS, considering
the stimulation parameters used here, is also a safe and well-
tolerated procedure in patients with DOC.
Our results should be interpreted with caution considering the
lack of a control group and the small sample size. However, the per-
centage of responders was unusual high considering the chronicity
required for inclusion [9]. Additionally, all subjects included showed
no noticeable behavioral changes according to CRS-R scores in the
month before inclusion. Finally, the pattern of responders described
here is consistent with what is already known in the literature
regarding brain stimulation in patients with DOC [5,8,10].
In conclusion, this exploratory study provides preliminary data
suggesting that transauricular VNS could be a safe and effective
tool to facilitate consciousness recovery in severely brain-injured
patients. These promising findings deserve confirmation in a
well-controlled clinical trial, especially considering that this tech-
nique seems to be safe, affordable, technically easy to handle and
well-tolerated in this population.
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